Search for: "Warner Chilcott Company Inc."
Results 1 - 20
of 24
Sorted by Relevance
|
Sort by Date
29 Apr 2013, 2:53 pm
In Warner Chilcott Company, LLC v. [read post]
25 Nov 2007, 6:03 pm
Warner Chilcott Holdings Co., D.D.C., No. 05-2195, 11/6/07). [read post]
1 Apr 2014, 8:55 am
Warner Chilcott Company, LLC v. [read post]
25 Nov 2012, 5:42 pm
USA, Inc., 432 F. [read post]
29 Aug 2011, 7:56 am
Prior to that, he spent 17 years with Warner-Lambert, which is now part of Pfizer, Inc. [read post]
9 Oct 2009, 9:11 am
9/9: Warner Chilcott Company LLC v. [read post]
28 Oct 2013, 7:23 am
Warner Chilcott Company LLC v. [read post]
26 Sep 2013, 7:11 am
Warner Chilcott Company, LLC v. [read post]
20 Oct 2011, 7:53 am
Famy Care, a Mumbai-based women healthcare speciality company, jointly with global generic company Mylan Inc. has entered into a settlement agreement with Warner Chilcott resolving ongoing paragraph IV lawsuit related to Femcon Fe chewable tablets, an oral low-dose (28-days) contraceptive regimen of 21 active chewable tablets of norethindrone and ethinyl estradiol (EE) combination followed by 7 [read post]
5 Apr 2011, 2:35 pm
There are two patents listed in the Orange Book for Warner Chilcott Pharmaceuticals, Inc. [read post]
9 Nov 2021, 2:54 pm
Prior authorization requirements are a common hurdle to increased drug sales and, as the earlier cases against Warner-Chilcott and Insys show, pharmaceutical companies have an incentive to overcome those requirements, sometimes by fraud. [read post]
8 May 2009, 8:00 am
(Property intangible) US: Supreme Court rules 9-0 that CAFC has jurisdiction to review case remanded by district court to state court: Carlsbad Technology Inc v HIF Bio, Inc et al (Managing Intellectual Property) (Patently-O) US: Anticipation by a laundry list of prophetic DNA sequences: In re Gleave (Holman's Biotech IP Blog) US: Reverse payment settlements and biotechnology (Holman's Biotech IP Blog) US: Biogen seeks review and correction of patent term adjustment… [read post]
28 Feb 2022, 10:46 am
With concentration in the areas of health care and tax fraud, Stephen has represented relators in cases against CareCore National, Warner Chilcott and Life Spine, Inc., and led the first settlement ever reached under the 2010 tax whistleblower amendments to New York’s False Claims Act. [read post]
9 Jul 2020, 10:56 am
Warner Chilcott plc, et al., in which $125 million was recovered in connection with a sprawling healthcare scheme. [read post]
19 Nov 2020, 8:08 pm
Warner Chilcott plc, et al., in which $125 million was recovered in connection with a sprawling healthcare scheme. [read post]
9 Jul 2020, 10:56 am
Warner Chilcott plc, et al., in which $125 million was recovered in connection with a sprawling healthcare scheme. [read post]
18 Jan 2023, 1:21 pm
With concentration in the areas of health care and tax fraud, Stephen has represented relators in cases against CareCore National, Warner Chilcott and Life Spine, Inc., and led the first settlement ever reached under the 2010 tax whistleblower amendments to New York’s False Claims Act. [read post]
15 Jun 2011, 4:56 am
(Patent Docs) Gemzar (Gemcitabine) – ALJ Rogers rules on motion to quash in Certain Gemcitabine (337-TA-766) (ITC Law Blog) Oestrin 24 Fe (Norethindrone acetate, Ethinyl estradiol) – US: Patent infringement complaint filed in response to Para IV certification: Warner Chilcott Co. v. [read post]
10 Feb 2010, 4:47 pm
(Patent Docs) Doryx (Doxycycline) – US: Warner Chilcott files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs) Ebixa (Memantine) – Canada: Duty of good faith patent prosecution: Lundbeck v Ratiopharm (IP Osgoode) Focalin (Dexmethylphenidate) - US: Settlement announced in Focalin infringement dispute involving Celgene, Novartis Pharmaceuticals and Teva Pharmaceuticals (Patent Docs) Gemzar (Gemcitabine) – US: Patent infringement… [read post]
7 Sep 2011, 4:22 am
Highlights this week included: US: CAFC: Immunisation methods are patent eligible: Classen Immunotherapies, Inc v Biogen IDEC et al (Inventive Step) (Orange Book Blog) (Patently-O) (Patent Docs) (Patent Docs) (IPBiz) (Patent Law Practice Center) (Patent Baristas) US: FTC issues long-awaited final report on authorized generics; report examines both the short-term effects and long-term impact on competition and drug prices (FDA Law Blog) (Orange Book Blog) Please join the… [read post]